Table 2 Patient characteristics during combined imatinib/IFN-α therapy

From: Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

Patient Disease status at IFN-α start Interval imatinib start to IFN-α addition (months) DFS (mo.) since imatinib start Site of relapse Relapse therapy Duration of combination (months) OS (mo.) since imatinib start Outcome
1 MRD+ 3.4 21.4+ 18+ 21.4+ Ongoing CHR, MRD decline
2 MRD+ 4.8 20.81+ 16+ 20.8+ Ongoing CHR, MRD−
3 MRD+ 3.5 9 Isolated CNS relapse i.t. therapy, CNS-irr., imatinib+IFN-α 17+* 20.5+ Ongoing CHR, MRD−
4 MRD+ 3.8 6.4 Isolated CNS relapse i.t. therapy, CNS-irr., imatinib+IFN-α 15.3+** 19.1+ Ongoing CMR, MRD−
5 MRD+ 4 5 BM relapse 6-MP, MTX, imatinib 1 10.5 Dead
6 Refractory first relapse, imatinib failure 0.5 5.4 BM relapse Second auto-SCT, MUD-SCT 5 14.3 Dead
Median (range)   3.7 (0.5–4.8) 8 (5–21.4+)    15.7 (1–18+) 20 (10.5–21.4+)  
  1. MRD=minimal residual disease by TaqMan-PCR; DFS=disease-free survival calculated from start of imatinib; CMR=complete marrow response; CHR=complete hematologic response; +=ongoing; *=4 weeks interruption; **=2 weeks interruption; OS=overall survival.